P236

The Role of Descending Serotonergic Mechanisms in Anti-hyperalgesic Effect of Zonisamide in a Rat Model for Painful Diabetic Neuropathy

N Bektas, R Arslan. Anadolu University Faculty of Pharmacy, Pharmacology, 26470, Turkey

The aim of this study was to demonstrate the role of descending serotonergic mechanisms in antihyperalgesic effectiveness of zonisamide (25 and 50 mg/kg *i.p.*), second generation antiepileptic drug, in a rat model for painful diabetic neuropathy. Diabetic neuropathy was induced by single injection of streptozotocin (STZ) (50 mg/kg; i.v.) in male and female Wistar rats (200-250 g) [Oh et al., 2006]. The hot-plate (HP), tail-immersion (TI), and paw pressure withdrawal (PPW) tests were performed to determine thermal and mechanical thresholds 40 min after injection of test drugs (at 22±1°C, between 10:00 and 18:00 h) [Eddy and Leimback, 1953; Schmauss and Yaksh, 1984; Beyreuther et al., 2006]. The statistical analyses were performed by one-way analysis of variance (ANOVA), followed by Tukey's multiple comparison tests. Differences were considered significant when $P \le 0.05$. Zonisamide (ZNS) at the doses of 25 and 50 mg/kg [n=10] showed significant anti-hyperalgesic effect as morphine (5 mg/kg) and carbamazepine (32 mg/kg) [n=7], reference drugs, in 3-week diabetic rats [(25 mg/kg ZNS: P<0.001 in HP and PPW tests; P<0.01 in TI test), (50 mg/kg ZNS: P<0.001 in HP, TI and PPW tests), (5 mg/kg morphine: P<0.001 in HP,TI and PPW tests), (32 mg/kg carbamazepine: P<0.001 in HP and TI tests; P<0.01 in PPW test)]. Selective 5-HT₂ antagonist ketanserine (1mg/kg), and selective 5-HT₃ receptor antagonist ondansetron (1mg/kg) [n=10], were used to investigate the role of descending serotonergic pathways in anti-hyperalgesic effects of zonisamide and injected (i.p.) 30 min before the doses of ZNS. Each antagonist reversed the effect of zonisamide in the hot-plate and tailimmersion tests significantly [(Ketanserin+25 mg/kg ZNS: P<0.01 in HP test; P<0.05 in TI test, Ondansetron+25 mg/kg ZNS: P<0.001 in HP test; P<0.05 in TI test), (Ketanserin+50 mg/kg ZNS and Ondansetron+50 mg/kg ZNS: P<0.001 in HP and TI tests)], however relatively in paw pressure withdrawal tests. These results indicate that 5-HT₂ and 5-HT₃ receptors in descending serotonergic pain inhibitory pathways play a role anti-hyperalgesic effect of zonisamide in inhibiting of sensing thermal stimuli, not exactly in mechanical stimuli.

References:

Beyreuther B et al., (2006) Eur J Pharmacol 539: 64-70.

Eddy NB and Leimback D (1953) J Pharmacol Exp Ther 107: 385-393.

Oh et a., (2006). Diabetes Res Clin Pract 71: 233-240.

Schmauss C and Yaksh TL (1984) J Pharmacol Experimen Ther 228: 1-12.